Humana Press eBooks · 2005 · 22 citations · 20 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyTumor MicroenvironmentCancer MetabolismCellular Responses To HypoxiaChemotherapy ResistanceCytotoxic ChemotherapyHypoxia AdaptationPharmacodynamics Of Anticancer AgentsAnticancer ChemotherapyAnticancer Drug ResistanceHypoxiaHypoxia-induced RadioresistanceHypoxia-mediated RadioresistanceHypoxic MicroenvironmentPreclinical Cancer Drug TestingPreclinical Drug Testing
Highly aggressive, rapidly growing tumors are often hypoxic, owing to an inadequate supply relative to consumption of oxygen (O2) in the expanding tumor mass, or growth in tissues with physiologically low O2 concentrations (such as bone marrow). Selection of tumor cells that can grow or survive under hypoxic conditions appears from both experimental and clinical studies to impact tumor progression, response to therapy, and to increase resistance to radiation and to certain cytotoxic drugs. Therefore, the predictive value of preclinical testing of anticancer agents in cell culture might be improved by conducting testing in conditions of physiological hypoxia. We review the impact of hypoxia on anticancer drug cytotoxicity and the methods used in our laboratory to asses the cytotoxic activity of single antineoplastic drugs under conditions of physiological hypoxia.
20
Biological consequences of tumor hypoxia
Michael Höckel · Seminars in Oncology · 2001 · 356 citations
Medicine, Cancer Biology, Oncology +14
Helen B. Stone, J. Martin Brown, Theodore L. Phillips et al. · Radiation Research · 1993 · 304 citations
Britta Maurer, Leonid S. Metelitsa, Robert C. Seeger et al. · JNCI Journal of the National Cancer Institute · 1999 · 289 citations · Full text
Medicine, Oncology, Pharmacology +15
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Nino Keshelava, Juan Zuo, P Chen et al. · PubMed · 2001 · 234 citations
Medicine, Oncology, Pharmacology +15